Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.23 (
MMP
)
4,246
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tissue factor pathway inhibitor-2
(
TFPI-2
) is a potent inhibitor of plasmin, a protease which is involved in tumour progression by activating (MMPs). This therefore makes
TFPI-2
a potential inhibitor of invasiveness and the development of metastases. In this study, low levels of
TFPI-2
expression were found in 65% of patients with small cell lung cancer (SCLC), the most aggressive type of lung cancer. To study the impact of
TFPI-2
in tumour progression,
TFPI-2
was overexpressed in NCI-H209 SCLC cells which were orthotopically implanted in nude mice. Investigations showed that
TFPI-2
inhibited lung tumour growth. Such inhibition could be explained in vitro by a decrease in tumour cell viability, blockade of G1/S phase cell cycle transition and an increase in apoptosis shown in NCI-H209 cells expressing
TFPI-2
. We also demonstrated that
TFPI-2
upregulation in NCI-H209 cells decreased
MMP
expression, particularly by downregulating MMP-1 and MMP-3. Moreover,
TFPI-2
inhibited phosphorylation of the MAPK signalling pathway proteins involved in the induction of
MMP
transcripts, among which MMP-1 was predominant in SCLC tissues and was inversely expressed with
TFPI-2
in 35% of cases. These results suggest that downregulation of
TFPI-2
expression could favour the development of SCLC.
...
PMID:Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. 2390 12
